Zobrazeno 1 - 7
of 7
pro vyhledávání: ''
Autor:
David Miles, José Baselga, Sandra M. Swain, Adam Knott, Graham Ross, Dino Amadori, Patrapim Sunpaweravong, Emma Clark, Vladimir Semiglazov
Publikováno v:
Breast Cancer Research and Treatment
Although the incidence of cancer increases with age, older patients are under-represented in cancer treatment trials, resulting in limited data availability in this patient population. Here we present results from pre-defined subgroup analyses conduc
Autor:
Roy Nitulescu, Tripthi Kamath, Marjolaine Gauthier-Loiselle, Annie Guerin, Anthony Masaquel, Kenneth More, Raluca Ionescu-Ittu, Nicholas Sicignano, Brian Barnett, Christopher Gallagher, Elizabeth Butts, Eric Q. Wu
Publikováno v:
Breast Cancer Research and Treatment
Trastuzumab reduces the risk of relapse in women with HER2-positive non-metastatic breast cancer, but little information exists on the timing of trastuzumab initiation. The study investigated the impact of delaying the initiation of adjuvant trastuzu
Autor:
Wilma L. Lingle, Beiyun Chen, Michael F. Press, Howard M. Stern, Monica M. Reinholz, Mona Shing, Edith A. Perez, Robert B. Jenkins, Amylou C. Dueck, Soonmyung Paik, Reid G. Meyer, Melanie Finnigan, Marc Buyse, JoAnne Zujewski, Ivonne Villalobos, Dennis J. Slamon, Chungyeul Kim, Anne E. Wiktor
Publikováno v:
Breast Cancer Research and Treatment
A comprehensive, blinded, pathology evaluation of HER2 testing in HER2-positive/negative breast cancers was performed among three central laboratories. Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) analyses were performed o
Autor:
Tejal Patel, Donald W. Northfelt, S. P. Kahanic, Sandra X. Franco, Edith A. Perez, Ismael Ghanem-Cañete, Robert B. Jenkins, David B. Johnson, Frances M. Palmieri, Gerardo Colon-Otero, Ann E. McCullough, Alvaro Moreno-Aspitia, Shaker R. Dakhil, Richard J. Rodeheffer, Kathleen S. Tenner, Amylou C. Dueck
Publikováno v:
Breast Cancer Research and Treatment
Lapatinib adds to the efficacy of trastuzumab in preclinical models and also in the neo-adjuvant setting. This study assesses the safety and feasibility of adding lapatinib to paclitaxel and trastuzumab (THL) as part of the adjuvant therapy for HER2-
Autor:
Suhail M. Ali, Yuping Tan, Allan Lipton, Christian F. Singer, Jeffrey S. Larson, Thomas Sherwood, Reinhard Horvat, Gordon Parry, Mojgan Haddad, A. Paquet, Jeff Sperinde, Kim Leitzel, Yolanda Lie, Xueguang Jin, John Winslow, Ahmed Chenna, Weidong Huang, Yining Shi, Joyee Banerjee, Jodi Weidler, Jennifer W. Cook, Wolfgang J. Köstler, Michael Bates, Alicia Newton, Ali Mukherjee, Eva Marie Fuchs, Laurie Goodman, Christos J. Petropoulos, Stephen Williams
Publikováno v:
Breast Cancer Research and Treatment
Trastuzumab is effective in the treatment of HER2/neu over-expressing breast cancer, but not all patients benefit from it. In vitro data suggest a role for HER3 in the initiation of signaling activity involving the AKT–mTOR pathway leading to trast
Autor:
Joanna Pikiel, Michelle DeSilvio, Piotr Potemski, Wolfgang Janni, Elżbieta Starosławska, Kathryn Jane Briggs, Christian Caglevic, Etienne Brain, Christos Papadimitriou, Tomasz Sarosiek, Boguslawa Karaszewska, Luca Marini, Christoph Salat
Publikováno v:
Breast Cancer Research and Treatment
Lapatinib is approved in combination with capecitabine for treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) who have progressed on prior trastuzumab in the metastatic setting. Vinorelb
Autor:
Sven Wind, Lisa A. Carey, Susan Cleator, Tamas Hickish, Duncan Wheatley, Nan Lin, Richard Vinisko, Laurie Frakes, Martina Uttenreuther-Fischer, David S. Mendelson, Steve Kelly, Stephen Houston, Hilary Jones, Agustin A. Garcia, Eric P. Winer, Pamela N. Munster
Publikováno v:
Breast Cancer Research and Treatment
Afatinib is an oral, ErbB family blocker, which covalently binds and irreversibly blocks all kinase-competent ErbB family members. This phase II, open-label, single-arm study explored afatinib activity in human epidermal growth factor receptor 2 (HER